Amelioration of experimental autoimmune myasthenia gravis rats by blood purification treatment using 4-mercaptoethylpyridine-based adsorbent.

The role of immunoadsorption therapy is well established in the management of myasthenia gravis (MG), an autoimmune disorder characterized by muscle weakness and caused by circulating IgG antibodies with specificity against the acetylcholine receptor. Conventional immunoadsorbents that employ recombinant protein A as immobilized ligand suffer from the drawbacks of high cost and low stability. The objective of this work is to assess the safety and efficacy of a synthetic adsorbent for treating MG. Adsorption columns were prepared from a Sepharose-based adsorbent coupled to 4-mercaptoethylpyridine (MEP), which acted as immobilized ligands. Animal model of experimental autoimmune MG (EAMG) using Lewis rats was developed and treated by whole blood perfusion. The results showed that the treatments provided a significant amelioration of clinical weakness for EAMG rats, with clinic score decreasing from 2.08 ± 0.38 to 1.25 ± 0.27. After a treatment session of about 1.5 h, blood cell counts were not significantly changed. Serum levels of total IgG and acetylcholine receptor antibody were reduced by 37.1 ± 6.5% and 35.6 ± 8.6%, respectively. In addition, reduction in complement components C3 (47.1 ± 6.7%), C4 (34.3 ± 3.4%), inflammatory cytokines interleukin-17 (10.4 ± 2.7%), and tumor necrosis factor-α (8.2 ± 3.1%) were also observed. This study demonstrated that MEP-based adsorbent not only removed pathogenic autoantibodies directly from the blood as with protein A adsorbents but also modulated cellular immunity through removal of complement components and related proinflammatory cytokines, thereby providing a potentially superior strategy for the treatment of MG.

[1]  Hulun Li,et al.  Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis , 2009, Immunology.

[2]  J. Xie,et al.  Removal of autoantibodies by 4-mercaptoethylpyridine-based adsorbent. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  B. Gong,et al.  Novel complement inhibitor limits severity of experimentally myasthenia gravis , 2009, Annals of neurology.

[4]  F. Shi,et al.  CCL2 recruitment of IL‐6‐producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17‐dependent B cell‐mediated autoimmunity , 2008, European journal of immunology.

[5]  Monica Milani,et al.  CD4+ T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis , 2008, Annals of the New York Academy of Sciences.

[6]  P. Christadoss,et al.  Classical Complement Pathway in Experimental Autoimmune Myasthenia Gravis Pathogenesis , 2008, Annals of the New York Academy of Sciences.

[7]  B. Gong,et al.  Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis1 , 2007, The Journal of Immunology.

[8]  A. Roque,et al.  Affinity-based methodologies and ligands for antibody purification: advances and perspectives. , 2007, Journal of chromatography. A.

[9]  R. Caspi,et al.  C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-γ Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells1 , 2007, Journal of Immunology.

[10]  J. Lohr,et al.  Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease , 2006, The Journal of experimental medicine.

[11]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[12]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[13]  D. Falkenhagen,et al.  Development of specific adsorbents for human tumor necrosis factor-alpha: influence of antibody immobilization on performance and biocompatibility. , 2005, Biomacromolecules.

[14]  A. Mamalaki,et al.  Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor α-subunit. Development of an antigen-specific therapeutic strategy , 2005, Journal of Neuroimmunology.

[15]  S. Cramer,et al.  Protein Interactions in Hydrophobic Charge Induction Chromatography (HCIC) , 2005, Biotechnology progress.

[16]  H. Hirasawa,et al.  Cytokine Adsorptive Property of Various Adsorbents in Immunoadsorption Columns and a Newly Developed Adsorbent: An in vitro Study , 2004, Blood Purification.

[17]  A. Annoni,et al.  Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-Subunit Induces Experimental Myasthenia Gravis in Rats 1 , 2004, The Journal of Immunology.

[18]  S. Higgs,et al.  Genetic Evidence for Involvement of Classical Complement Pathway in Induction of Experimental Autoimmune Myasthenia Gravis 1 , 2003, The Journal of Immunology.

[19]  B. Scallon,et al.  Anti-TNF-α Antibodies Suppress the Development of Experimental Autoimmune Myasthenia Gravis , 2002 .

[20]  J. Zeitlhofer,et al.  Long‐term treatment of myasthenia gravis with immunoadsorption , 2002, Journal of clinical apheresis.

[21]  M. Takamori,et al.  Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[22]  E. Boschetti,et al.  A dual-mode approach to the selective separation of antibodies and their fragments. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[23]  E. Boschetti,et al.  New method for the selective capture of antibodies under physiolgical conditions , 2000, Bioseparation.

[24]  J. Oger,et al.  Clinical evaluation of a staphylococcal protein A immunoadsorption system in the treatment of myasthenia gravis patients , 1999, Transfusion.

[25]  H. Link,et al.  Cytokines and the pathogenesis of myasthenia gravis , 1997, Muscle & nerve.

[26]  J. Kuks,et al.  Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients , 1997, Journal of Neurology.

[27]  F. Mokhtarian,et al.  Treatment of myasthenia gravis by immunoadsorption of plasma , 1995, Neurology.

[28]  R. Mantegazza,et al.  Immunosuppressive Treatments: Their Efficacy on Myasthenia Gravis Patients' Outcome and on the Natural Course of the Disease a , 1993, Annals of the New York Academy of Sciences.

[29]  R. Watt,et al.  Therapeutic protein A immunoadsorption. A review , 1990 .

[30]  P. Christadoss.  C5 gene influences the development of murine myasthenia gravis. , 1988, Journal of immunology.